HOME >> BIOLOGY >> NEWS
Gene therapy breakthrough offers hope to patients with inherited high cholesterol levels

New research published in BMC Molecular Biology explains how a new technique for introducing genes into mammalian cells using the virus responsible for warts could be a major step forward in developing gene therapy treatments for people with familial hypercholesterolemia (FH), a genetic disease that affects around 12 million people worldwide.

People with FH have a genetic defect that prevents their liver cells from absorbing chlolesterol in the form of low density lipoprotein (LDL). This leads to high levels of cholesterol in the bloodstream increasing the risk of heart disease. It is estimated that about half of men and a third of women with FH suffer a heart attack by the age of 60.

FH occurs as a result of a single defective gene that codes for a LDL receptor in the liver. Many single gene defects like the one that causes FH are candidates for gene therapy, a medical treatment used to repair or replace faulty genes (this is because it is much easier to repair one gene that causes a disease than it is to tackle other genetic diseases that involves several faulty genes).

Since the first successful attempts at gene therapy in 1990 there has been an intense research effort to develop ways of curing genetic diseases. By 1996 over 3000 patients had been treated using gene therapy, but most of these cases were unsuccessful. There are major obstacles to overcome to increase the success of gene therapy trials. Firstly, ways of getting multiple copies of healthy genes into enough cells to reverse the underlying disease need to be established. Secondly, it is important that the expression of healthy genes is sustained and finally any virus used to repair or replace faulty genes must not be attacked by the immune system of the patient receiving gene therapy.

The research published in BMC Molecular Biology showed that the virus responsible for warts (bovine papilloma virus) could be used to restore the function of cells with defective LDL recep
'"/>

Contact: Gordon Fletcher
gordon@biomedcentral.com
44-20-7323-0323
BioMed Central
14-May-2002


Page: 1 2

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/18/2019)... ... April 18, 2019 , ... As the industry ... popular trial design that have the potential to increase patient recruitment and retention. ... sponsors due to the complexity of regulations, potential cost implications and a multitude ...
(Date:4/18/2019)... CREEK, Calif. (PRWEB) , ... April 18, 2019 ... ... for the healthcare industry, today announced the launch of mSource® AI Contract Text ... extract deep knowledge of Medpricer customers’ supplier contracts, truly optimizing purchased services spend ...
(Date:4/17/2019)... ... April 17, 2019 , ... Quartesian LLC, a ... clinical trial sponsors, has entered into a multi-year agreement with Medrio, a leading ... member of Medrio’s Certified Partner Program, to leverage the full range of Medrio’s ...
Breaking Biology News(10 mins):
(Date:4/18/2019)... Mass. (PRWEB) , ... April 18, 2019 , ... ... fossil fuels, a research team that includes a chemical engineer at Worcester Polytechnic ... exotic microorganism that may make it possible to manufacture isobutanol and other biofuels ...
(Date:4/16/2019)... , ... April 16, 2019 , ... ... Sources and their project partner, the U.S. Army Center for Environmental Health Research ... Biomonitor Through Combined In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company located at the ...
(Date:4/16/2019)... ... April 16, 2019 , ... Fulcrum ... today announced that Bank South Pacific (BSP), the largest regionally owned bank in ... awarded Fulcrum a contract to deliver a fingerprint-based Know Your Customer (KYC) banking ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, Inc., a developer of ... plant expansion to increase production of methylene malonate monomers and oligomers. , The ... Sirrus’ full-scale production facility, which is scheduled to break ground in 2019. “The ...
Breaking Biology Technology:
Cached News: